JP Morgan Upgrades Bioventus to Neutral, Raises Price Target to $13
Bioventus: Strategic Moves Amidst Financial Challenges Justify Hold Rating
J.P. Morgan Upgrades Bioventus(BVS.US) to Hold Rating, Raises Target Price to $13
Express News | Bioventus Inc : JP Morgan Raises to Neutral From Underweight; Raises Target Price to $13 From $12
Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet
Earnings Call: Bioventus Reports Robust Q3 Growth, Raises Full-year Guidance
Bioventus Is Maintained at Buy by Canaccord Genuity
Bioventus Analyst Ratings
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $17
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $15
J.P. Morgan Maintains Bioventus(BVS.US) With Sell Rating, Announces Target Price $12
Bioventus (BVS) Gets a Sell From J.P. Morgan
Q3 2024 Bioventus Inc Earnings Call
Express News | Bioventus Inc : Canaccord Genuity Raises Target Price to $15 From $12
Bioventus Reports Strong Revenue Growth in Q3 2024
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript Summary
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript
12 Health Care Stocks Moving In Tuesday's Intraday Session
Bioventus' Shares Down in Early Trading Amid Higher Q3 Results